Results 81 to 90 of about 11,885 (204)

Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4915-4925, June 2026.
ABSTRACT Aims Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all‐cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes.
Ji Eun Jun, Seohyun Kim, In‐Kyung Jeong, Jae Hyeon Kim   +3 more
wiley   +1 more source

Synergistic Effects of Galantamine and Memantine in Attenuating Scopolamine-Induced Amnesia in Mice

Journal of Pharmacological Sciences, 2012
We investigated a possible drug efficacy enhancement obtained by combining inactive doses of galantamine and memantine in the scopolamine-induced amnesia model in mice.
Perrine Busquet, Valeria Capurro, Andrea Cavalli, Daniele Piomelli, Angelo Reggiani, Rosalia Bertorelli   +5 more
doaj   +1 more source

Acetylcholinesterase Inhibitor Ameliorates Early Cardiometabolic Disorders in Fructose-Overloaded Rat Offspring

Pharmaceuticals
Background: We investigate the role of galantamine on autonomic dysfunction associated with early cardiometabolic dysfunction in the offspring of fructose-overloaded rats.
Victor Hugo Martins de Miranda, Camila Paixão Dos Santos, Pietra Petrica Neves, Antonio Viana Nascimento-Filho, Marina Rascio Henriques Dutra, Nathalia Bernardes, Maria Claúdia Irigoyen, Kátia De Angelis   +7 more
doaj   +1 more source

Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01) Efeitos da galantamina sobre a memória e a atenção na doença de Alzheimer medidos por testes neuropsicológicos computadorizados: resultados do Estudo Multicêntrico com Galantamina (GAL-BRA-01)

Arquivos de Neuro-Psiquiatria, 2004
OBJECTIVE: To investigate the effects of galantamine on the performance of patients with mild to moderate Alzheimer's disease (AD) in a computerized neuropsychological test battery (CNTB).
Paulo Caramelli, Márcia L.F. Chaves, Eliasz Engelhardt, João Carlos B. Machado, Rodrigo R. Schultz, Francisco A.C. Vale, Helenice Charchat-Fichman   +6 more
doaj   +1 more source

Safety and efficacy of galantamine in subjects with mild cognitive impairment.

, 2008
OBJECTIVE: To assess the safety of galantamine in subjects with mild cognitive impairment (MCI), the ability of galantamine to benefit cognition and global functioning in subjects with MCI, and the ability of galantamine to delay conversion to dementia ...
Nye, J. S., Winblad, B., Wang, D, Mayorga, AJ, Nye, JS, Mayorga, A J, Brashear, H R, Feldman, H, Feldman, H., Wilcock, G. K., Wilcock, GK, Truyen, L, Mayorga, A. J., Brashear, HR, Wallin, Anders,, Scinto, L., Wang, D., Wilcock, G K, Nye, J S, Gauthier, S, Brashear, H. R., Gauthier, S., Scinto, L, Wilcock, Gordon, Truyen, L., Winblad, B   +25 more
core   +1 more source

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application [PDF]

, 2013
Introduction: Patients with Alzheimer's disease (AD) are currently treated with cholinesterase inhibitors, such as galantamine, without actual knowledge of its concentration in plasma.
Åsa K Wallin, Carina Wattmo, Jedenius, Erik, Blennow, Kaj, Wattmo, Carina, Erik Jedenius, Wallin, Åsa, Kaj Blennow   +7 more
core   +1 more source

Galantamine as a Potential Treatment for Peripheral Nerve Injuries: Emphasis on Non-Systemic Delivery

Future Pharmacology
Peripheral nerve injuries can lead to significant functional impairments, and treatment options remain limited. Galantamine, widely used for cognitive disorders, has shown potential effects on the peripheral nervous system, making it a candidate for new ...
Mariya Ivanova, Liliya Panayotova-Ovcharova, Detelina Nedyalkova-Petkova, Petar Petkov, Georgi Boshev, Evgeniya Vladeva   +5 more
doaj   +1 more source

Development of transfersomal buccal patches of galantamine for enhanced bioavailability in Alzheimer’s disease therapy

Journal of Applied Pharmaceutical Research
Background: Galantamine, an acetylcholinesterase inhibitor used in Alzheimer’s disease, exhibits low and variable bioavailability due to gastrointestinal metabolism and first-pass hepatic elimination. Buccal drug delivery offers a non-invasive route that
Pavuluri Chandrasekhar, Rajaganapathy Kaliyaperumal   +1 more
doaj   +1 more source

Sleep and memory problems: acetylcholine in some neurodegenerative diseases, use of an extended-release formulation of galantamine

Неврология, нейропсихиатрия, психосоматика, 2012
The paper reviews the literature dedicated to an association between sleep and memory problems and acetylcholine (AC) levels. Moderate impairments of circadian rhythms can develop with aging; however, these changes become quite significant in dementia ...
I V Litvinenko
doaj   +1 more source

Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats.

, 2008
Acetylcholine (ACh) esterase inhibitors like galantamine and donepezil have been tested as adjunct treatment in schizophrenia. Although ACh esterase inhibition might confer some antipsychotic activity, the role of allosteric potentiation of nicotinic ACh
Schilstrom, B,, Wiker, Charlotte,, Wiker, C, Wadenberg, Marie-Louise,, Schilström, Björn, Wiker, Charlotte, Sandbäck, Carina,, Svensson, Torgny,, Svensson, Torgny, Sandack, C, Wadenberg, Marie-Louise, Svensson, TH, Schilström, Björn,, Wadenberg, M-L, Sandbäck, Carina   +14 more
core   +1 more source